BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman Sells 987 Shares

BioLife Solutions, Inc. (NASDAQ:BLFS) CFO Troy Wichterman sold 987 shares of the stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total value of $26,668.74. Following the completion of the transaction, the chief financial officer now owns 121,779 shares in the company, valued at approximately $3,290,468.58. The trade was a 0.80 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Troy Wichterman also recently made the following trade(s):

• On Tuesday, November 26th, Troy Wichterman sold 581 shares of BioLife Solutions stock. The stock was sold at an average price of $27.20, for a total value of $15,803.20.
• On Tuesday, November 12th, Troy Wichterman sold 147 shares of BioLife Solutions stock. The stock was sold at an average price of $26.19, for a total value of $3,849.93.
• On Wednesday, October 30th, Troy Wichterman sold 894 shares of BioLife Solutions stock. The stock was sold at an average price of $23.15, for a total value of $20,696.10.

BioLife Solutions Price Performance

BLFS stock traded up $0.58 during midday trading on Wednesday, hitting $27.69. 270,111 shares of the stock were exchanged, compared to its average volume of 217,162. The stock’s 50-day moving average price is $25.91 and its 200-day moving average price is $24.27. The stock has a market cap of $1.28 billion, a price-to-earnings ratio of -26.12 and a beta of 1.92. BioLife Solutions, Inc. has a fifty-two week low of $14.50 and a fifty-two week high of $28.88. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78.

Analyst Ratings Changes

BLFS has been the topic of several analyst reports. HC Wainwright lowered their target price on BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a research note on Monday, November 18th. Benchmark reiterated a “buy” rating and issued a $30.00 target price on shares of BioLife Solutions in a research note on Thursday, December 19th. TD Cowen lifted their target price on BioLife Solutions from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Northland Securities lifted their target price on BioLife Solutions from $28.00 to $31.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, KeyCorp raised their price target on BioLife Solutions from $30.00 to $33.00 and gave the company an “overweight” rating in a report on Friday, December 13th. One research analyst has rated the stock with a sell rating and seven have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $29.43.

Hedge Funds Weigh In On BioLife Solutions

Hedge funds and other institutional investors have recently bought and sold shares of the company. Fred Alger Management LLC increased its position in BioLife Solutions by 6.0% during the second quarter. Fred Alger Management LLC now owns 1,579,138 shares of the medical equipment provider’s stock worth $33,841,000 after buying an additional 88,840 shares in the last quarter. State Street Corp increased its position in BioLife Solutions by 7.3% during the third quarter. State Street Corp now owns 1,412,316 shares of the medical equipment provider’s stock worth $35,364,000 after buying an additional 95,788 shares in the last quarter. Geode Capital Management LLC increased its position in BioLife Solutions by 2.2% during the third quarter. Geode Capital Management LLC now owns 842,771 shares of the medical equipment provider’s stock worth $21,107,000 after buying an additional 18,473 shares in the last quarter. Dimensional Fund Advisors LP increased its position in BioLife Solutions by 9.1% during the second quarter. Dimensional Fund Advisors LP now owns 794,971 shares of the medical equipment provider’s stock worth $17,034,000 after buying an additional 66,422 shares in the last quarter. Finally, Rockefeller Capital Management L.P. increased its position in BioLife Solutions by 81.3% during the third quarter. Rockefeller Capital Management L.P. now owns 585,497 shares of the medical equipment provider’s stock worth $14,661,000 after buying an additional 262,504 shares in the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.